The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide ...
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...
THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...
Hims & Hers Health (NYSE:HIMS) is down 7% in early morning trading after the U.S. FDA determined that there is no shortage of ...
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...
Leerink notes that the FDA today declared an end to the tirzepatide shortage, which “seemingly begins the process of bringing the compounded ...
Credit: Eli Lilly. Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). Compounding pharmacies must now cease producing the lucrative ...
Tirzepatide includes injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss). The FDA first announced 2 months ago that any shortage of the medications observed during ...